These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8076660)

  • 1. Role of angiotensin converting enzyme inhibitors in patients with left ventricular dysfunction and congestive heart failure.
    McKelvie R; McConachie D; Yusuf S
    Eur Heart J; 1994 May; 15 Suppl B():9-13; discussion 26-30. PubMed ID: 8076660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of angiotensin-converting enzyme inhibitors in left ventricular dysfunction: results of the studies of left ventricular dysfunction in the context of other similar trials.
    Yusuf S; Garg R; McConachie D
    J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S28-35. PubMed ID: 7514238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
    Sigurdsson A; Swedberg K
    Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
    Foster RE; Johnson DB; Barilla F; Blackwell GG; Orr R; Roney M; Stanley AW; Pohost GM; Dell'Italia LJ
    Am Heart J; 1998 Aug; 136(2):269-75. PubMed ID: 9704689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?
    Cleland JG; Puri S
    Br Heart J; 1994 Sep; 72(3 Suppl):S81-6. PubMed ID: 7946810
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.
    Konstam MA
    Eur Heart J; 1995 Dec; 16 Suppl N():59-64. PubMed ID: 8682063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ventricular remodeling and its prevention in the treatment of heart failure.
    Patten RD; Udelson JE; Konstam MA
    Curr Opin Cardiol; 1998 May; 13(3):162-7. PubMed ID: 9649938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular remodeling and angiotensin-converting enzyme inhibitors.
    Goldstein S; Sabbah H
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S27-31. PubMed ID: 7700061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?
    Nelson KM; Yeager BF
    Ann Pharmacother; 1996 Sep; 30(9):986-93. PubMed ID: 8876861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical course of heart failure and its modification by ACE inhibitors: insights from recent clinical trials.
    Cleland JG
    Eur Heart J; 1994 Jan; 15(1):125-30. PubMed ID: 8174572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
    Cohn JN
    Am J Cardiol; 1993 Sep; 72(8):21C-24C; discussion 24C-26C. PubMed ID: 8372797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure.
    Ghali JK; Giles T; Gonzales M; Horswell R; Kumar S; Lejuene A; Livaudais GF; Sarkar IC
    J La State Med Soc; 1997 Dec; 149(12):474-84. PubMed ID: 9425858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE-inhibitors in coronary artery disease?
    Vogt M; Motz W; Strauer BE
    Basic Res Cardiol; 1993; 88 Suppl 1():43-64. PubMed ID: 8357335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.